

July 12, 2024

Everest Organics Limited: Ratings withdrawn

Summary of rating action

Instrument*	Previous Rated Amount (Rs. crore)	Current Rated Amount (Rs. crore)	Rating Action
Long-term – Fund-based – Cash Credit	16.00	16.00	[ICRA] B+ (Stable); withdrawn
Long-term – Fund-based – Term Loans	17.10	17.10	[ICRA] B+ (Stable); withdrawn
Short-term – Non-fund based	6.00	6.00	[ICRA]A4; withdrawn
Long-term/Short-term – Fund-based	7.00	7.00	[ICRA] B+ (Stable)/[ICRA]A4; withdrawn
Long-term – Unallocated	0.90	0.90	[ICRA] B+ (Stable); withdrawn
Total	47.00	47.00	

*Instrument details are provided in Annexure-I

Rationale

ICRA has withdrawn the ratings assigned to the bank facilities of **Everest Organics Limited** at the request of the company and confirmation from the company that they have not availed unallocated limits rated by ICRA from any of the banks and based on the No Objection Certificate received from the banker, which is in accordance with ICRA's policy on withdrawal. ICRA does not have information to suggest that the credit risk has changed since the time the rating was last reviewed.

The key rating drivers, liquidity position, rating sensitivities and key financial indicators have not been captured as the rated instruments are being withdrawn. The previous detailed rating rationale is available at the following link: [Click here.](#)

Analytical approach

Analytical Approach	Comments
Applicable rating methodologies	Corporate Credit Rating Methodology Policy on withdrawal of Credit Ratings Pharmaceuticals
Parent/Group support	Not Applicable
Consolidation/Standalone	The rating is based on the company's standalone financial profile.

About the company

Everest Organics Limited was established in 1993 by Dr. Srihari Raju. It is currently managed by his daughter, Dr. Sirisha Kakarlapudi, who is the new CEO of EOL. Initially incorporated as a private limited company, it went public and was listed on the BSE in 1995. The company manufactures APIs and intermediates such as Omeprazole, Esomeprazole, Pantoprazole, Chloro compound and Benzimidazole. Its manufacturing facility is at Aroor village, in the Medak district of Telangana, with an installed production capacity of 820 MTPA. The company is ISO 9001-2008 certified, while the plant is WHO-GMP certified. The manufacturing facility also received US FDA approval in June 2017.

Status of non-cooperation with previous CRA: Not applicable

Any other information: None

Rating history for past three years

Instrument	Type	Current rating (FY2025)		Chronology of rating history for the past 3 years			
		Amount Rated (Rs. crore)	Date & rating in FY2025	Date & rating in FY2024	Date & rating in FY2023		Date & rating in FY2022
			July 12, 2024	Aug 24, 2023	Aug 22, 2022	Jun 08, 2022	Dec 15, 2021
1 Cash Credit	Long Term	16.00	[ICRA] B+ (Stable); withdrawn	[ICRA]B+(Stable)	[ICRA]B+(Stable)	[ICRA]BB(Negative)	[ICRA]BB+(Stable)
2 Term Loans	Long Term	17.10	[ICRA] B+ (Stable); withdrawn	[ICRA]B+(Stable)	[ICRA]B+(Stable)	[ICRA]BB(Negative)	[ICRA]BB+(Stable)
3 Non - Fund Based	Short Term	6.00	[ICRA]A4; withdrawn	[ICRA]A4	[ICRA]A4	[ICRA]A4	[ICRA]A4+
4 Fund-Based	Long/ Short Term	7.00	[ICRA] B+ (Stable)/[ICRA]A4; withdrawn	[ICRA]B+(Stable)/[ICRA]A4	[ICRA]B+(Stable)/[ICRA]A4	[ICRA]BB(Negative)/[ICRA]A4	[ICRA]BB+(Stable)/[ICRA]A4+
5 Unallocated	Long Term	0.90	[ICRA] B+ (Stable); withdrawn	[ICRA]B+(Stable)	-	-	-

Complexity level of the rated instruments

Instrument	Complexity Indicator
Long Term – Fund based – Term Loan	Simple
Long Term – Fund based – Cash Credit	Simple
Short Term – Non Fund based	Very Simple
Long Term/Short Term – Fund based - Bill Discounting/ Export Packaging Credit	Simple
Long Term – Unallocated	Not Applicable

The Complexity Indicator refers to the ease with which the returns associated with the rated instrument could be estimated. It does not indicate the risk related to the timely payments on the instrument, which is rather indicated by the instrument's credit rating. It also does not indicate the complexity associated with analysing an entity's financial, business, industry risks or complexity related to the structural, transactional or legal aspects. Details on the complexity levels of the instruments are available on ICRA's website: [Click Here](#)

Annexure I: Instrument details

ISIN No	Instrument Name	Date of Issuance	Coupon Rate	Maturity	Amount Rated (Rs. Crore)	Current Rating and Outlook
NA	Cash Credit	-	-	-	16.00	[ICRA]B+ (Stable); withdrawn
NA	Term Loan	02/07/2021	-	FY2028	17.10	[ICRA]B+ (Stable); withdrawn
NA	Letter of Credit	-	-	-	5.50	[ICRA]A4; withdrawn
NA	Bank Guarantee	-	-	-	0.50	[ICRA]A4; withdrawn
NA	Bill discounting/Export Packaging Credit	-	-	-	7.00	[ICRA]B+ (Stable)/[ICRA]A4; withdrawn
NA	Unallocated	-	-	-	0.90	[ICRA]B+ (Stable); withdrawn

Source: Company

Annexure II: List of entities considered for consolidated analysis– Not Applicable

ANALYST CONTACTS

Shamsher Dewan

+91 124 4545328

shamsherd@icraindia.com

Srikumar Krishnamurthy

+91 44 4596 4318

ksrikumar@icraindia.com

Nithya Debbadi

+91 40 69396416

nithya.debbadi@icraindia.com

Etikala Ravi Teja

+91 40 69396418

etikala.teja@icraindia.com

RELATIONSHIP CONTACT

L. Shivakumar

+91 22 6114 3406

shivakumar@icraindia.com

MEDIA AND PUBLIC RELATIONS CONTACT

Ms. Naznin Prodhani

Tel: +91 124 4545 860

communications@icraindia.com

Helpline for business queries

+91-9354738909 (open Monday to Friday, from 9:30 am to 6 pm)

info@icraindia.com

About ICRA Limited:

ICRA Limited was set up in 1991 by leading financial/investment institutions, commercial banks and financial services companies as an independent and professional investment Information and Credit Rating Agency.

Today, ICRA and its subsidiaries together form the ICRA Group of Companies (Group ICRA). ICRA is a Public Limited Company, with its shares listed on the Bombay Stock Exchange and the National Stock Exchange. The international Credit Rating Agency Moody's Investors Service is ICRA's largest shareholder.

For more information, visit www.icra.in

ICRA Limited



Registered Office

B-710, Statesman House, 148, Barakhamba Road, New Delhi-110001
Tel: +91 11 23357940-45



Branches



© Copyright, 2024 ICRA Limited. All Rights Reserved.

Contents may be used freely with due acknowledgement to ICRA.

ICRA ratings should not be treated as recommendation to buy, sell or hold the rated debt instruments. ICRA ratings are subject to a process of surveillance, which may lead to revision in ratings. An ICRA rating is a symbolic indicator of ICRA's current opinion on the relative capability of the issuer concerned to timely service debts and obligations, with reference to the instrument rated. Please visit our website www.icra.in or contact any ICRA office for the latest information on ICRA ratings outstanding. All information contained herein has been obtained by ICRA from sources believed by it to be accurate and reliable, including the rated issuer. ICRA however has not conducted any audit of the rated issuer or of the information provided by it. While reasonable care has been taken to ensure that the information herein is true, such information is provided 'as is' without any warranty of any kind, and ICRA in particular, makes no representation or warranty, express or implied, as to the accuracy, timeliness or completeness of any such information. Also, ICRA or any of its group companies may have provided services other than rating to the issuer rated. All information contained herein must be construed solely as statements of opinion, and ICRA shall not be liable for any losses incurred by users from any use of this publication or its contents.